Robert Hazlett
Stock Analyst at BTIG
(0.52)
# 3,803
Out of 4,818 analysts
23
Total ratings
30%
Success rate
-26.39%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $5.79 | +314.51% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $0.69 | +480.89% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.15 | +1,117.39% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.09 | +21,950.72% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $104.33 | -6.07% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $7.18 | +735.65% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $3.98 | +1,482.91% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $9.61 | +201.93% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $2.26 | +1,150,342.48% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $2.16 | +177.78% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $12.45 | +44.58% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $5.79
Upside: +314.51%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $0.69
Upside: +480.89%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.15
Upside: +1,117.39%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.09
Upside: +21,950.72%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $104.33
Upside: -6.07%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $7.18
Upside: +735.65%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $3.98
Upside: +1,482.91%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $9.61
Upside: +201.93%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $2.26
Upside: +1,150,342.48%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $2.16
Upside: +177.78%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $12.45
Upside: +44.58%